Cencora Buys American Oncology Network for $2.4B

Cencora is set to significantly expand its oncology management services organization (MSO) capabilities through a definitive agreement to acquire American Oncology Network (AON) for approximately $2.4 billion. This strategic move is designed to enhance Cencora's support for independent oncology practices and extend its reach into 12 new states, bolstering its presence across the U.S. healthcare ecosystem.

The transaction values AON at roughly $2.4 billion, comprising an upfront payment of approximately $2.3 billion and up to $100 million in contingent value rights tied to specific performance benchmarks. This acquisition represents a substantial investment in community-based cancer care, aligning with the growing trend of consolidating specialized healthcare services to improve efficiency and patient access. Cencora, which already holds a 4% stake in AON, anticipates the deal will be accretive to its adjusted diluted earnings per share within two years post-completion.

AON, a physician-led network comprising over 350 oncology providers across 21 states, offers essential services, technology, and infrastructure to independent practices. This acquisition will empower AON with additional resources to broaden its integrated patient services, upgrade its technological and practice support infrastructure, and continue its physician and practice recruitment efforts. The deal structure allows for certain AON shareholders to retain up to 25% of the company's equity, with Cencora expecting to pay around $1.7 billion at closing if this rollover occurs, thereby increasing its ownership to 75%.

This consolidation arrives at a critical juncture for oncology care, where independent practices face increasing pressure from administrative burdens and the need for advanced treatment modalities. By integrating AON's established network, Cencora aims to fortify its position as a leading MSO, enabling physicians to maintain clinical decision-making authority while benefiting from enhanced operational and financial support. This strategy is expected to drive long-term value by improving the delivery of high-quality, cost-effective cancer care closer to patients' homes.

The transaction is subject to standard closing conditions, including regulatory approvals and the consent of AON shareholders. The strategic rationale is underscored by comments from Cencora CEO Robert P. Mauch, who highlighted the expansion of their physician-led MSO and support for community care. Similarly, AON CEO Todd Schonherz emphasized the agreement's focus on providing physicians, clinicians, and patients with greater resources and support, reinforcing AON's mission of accessible, physician-led cancer care.

Financial advisory for Cencora was led by Citi, with J.P. Morgan Securities also providing counsel. Legal guidance was provided by Holland & Knight and Sidley Austin. For the special committee of AON's Board of Directors, Moelis & Company served as exclusive financial advisor, with McDermott Will & Schulte acting as legal counsel to AON and Cleary Gottlieb Steen & Hamilton advising the special committee.

This acquisition follows a period of strong performance for Cencora, particularly within its U.S. Healthcare Solutions segment, which prompted the company to raise its fiscal 2026 adjusted earnings outlook to at least $17.90 per diluted share. The deal's successful integration is anticipated to further contribute to this positive financial trajectory.